Argenx reported that an independent data monitoring committee recommended stopping late‑stage trials of Vyvgart Hytrulo in thyroid eye disease after an interim analysis concluded the studies were unlikely to meet their endpoints. The company announced the decision publicly and said it will cease enrollment and dosing in the affected trials. Vyvgart Hytrulo, an autoimmune therapeutic, had been positioned for a potential indication expansion into thyroid eye disease. Argenx said the interim futility finding will change its development timeline and force reallocation of resources. The decision highlights the role of independent monitoring boards in limiting late‑stage spend when interim data show low probability of success.